GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Macrogenics Inc (NAS:MGNX) » Definitions » Net Margin %
中文

Macrogenics (Macrogenics) Net Margin % : -502.75% (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Macrogenics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Macrogenics's Net Income for the three months ended in Dec. 2023 was $-46.07 Mil. Macrogenics's Revenue for the three months ended in Dec. 2023 was $9.16 Mil. Therefore, Macrogenics's net margin for the quarter that ended in Dec. 2023 was -502.75%.

The historical rank and industry rank for Macrogenics's Net Margin % or its related term are showing as below:

MGNX' s Net Margin % Range Over the Past 10 Years
Min: -292.36   Med: -80   Max: -12.62
Current: -15.92


MGNX's Net Margin % is ranked better than
69.23% of 1027 companies
in the Biotechnology industry
Industry Median: -162.84 vs MGNX: -15.92

Macrogenics Net Margin % Historical Data

The historical data trend for Macrogenics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Macrogenics Net Margin % Chart

Macrogenics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -244.76 -132.71 -267.20 -79.83 -15.84

Macrogenics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.99 -156.98 437.49 168.84 -502.75

Competitive Comparison of Macrogenics's Net Margin %

For the Biotechnology subindustry, Macrogenics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Macrogenics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Macrogenics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Macrogenics's Net Margin % falls into.



Macrogenics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Macrogenics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-9.058/57.193
=-15.84 %

Macrogenics's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-46.072/9.164
=-502.75 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Macrogenics  (NAS:MGNX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Macrogenics Net Margin % Related Terms

Thank you for viewing the detailed overview of Macrogenics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Macrogenics (Macrogenics) Business Description

Traded in Other Exchanges
Address
9704 Medical Center Drive, Rockville, MD, USA, 20850
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. The company's strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates. The company also targets autoimmune disorders and infectious diseases. The company's intellectual property is characterized by its patent use to protect the composition of its product candidates and the technology used to create them.
Executives
Ezio Bonvini officer: Sr VP, Research & CSO 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Biotech Target N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Edward Hurwitz director
Jeffrey Stuart Peters officer: Acting General Counsel 9704 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Margaret Liu director C/O SANGAMO, POINT RICHMOND TECH CNTR II, 501 CANAL BLVD, SUITE A-100, RICHMOND CA 94804
Meenu Chhabra director C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103
James Karrels officer: SVP, CFO and Secretary 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
William K Heiden director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Thomas Spitznagel officer: Sr VP, BPD & Manufacturing 9704 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Biotech Ag Bb 10 percent owner SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200
Federica F. O'brien director C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Eric Blasius Risser officer: Sr VP & Chief Business Officer 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Kenneth Galbraith director OCEAN PARK RPO PO BOX 45025, 12851 16TH AVE, SURREY A1 V4A9L1
Stephen L. Eck officer: Chief Medical Officer 12212 TECHNOLOGY BLVD., AUSTIN TX 78727
Matthew K Fust director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949